Agomab Therapeutics reports that Pontifax-related reporting persons beneficially own 3,305,846 common shares representing 6.8% of the class as of 03/31/2026. The filing is a joint Schedule 13G showing shared voting and dispositive power over those shares and includes a Joint Filing Agreement dated April 16, 2026.
The ownership block consists of four Pontifax entities with shared control through Pontifax VI G.P. L.P. and Pontifax Management; Messrs. Tomer Kariv and Ran Nussbaum disclaim beneficial ownership of the underlying entity holdings per the filing.
Positive
None.
Negative
None.
Insights
Neutral disclosure of a passive institutional stake and shared control.
The Schedule 13G records a 6.8% ownership position held collectively by Pontifax entities, reported with shared voting and dispositive powers totaling 3,305,846 shares as of 03/31/2026. The joint filing and disclaimer language indicate entity-level beneficial ownership while two named directors disclaim personal beneficial ownership.
Watch future filings for any change to a Schedule 13D or Form 4, which would indicate active control or transactional intent; timing for any such disclosure is not provided in the excerpt.
Key Figures
Reported shares beneficially owned:3,305,846 sharesPercent of class:6.8%Reporting period date:03/31/2026+2 more
"This Statement is filed on behalf of Pontifax VI G.P. L.P."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Shared Voting Powerregulatory
"Shared power to vote or to direct the vote: 3,305,846"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Beneficial Ownershipfinancial
"Amount beneficially owned: 3,305,846"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Joint Filing Agreementregulatory
"Joint Filing Agreement, dated as of April 16, 2026"
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Agomab Therapeutics NV
(Name of Issuer)
Common Shares, no nominal value per share
(Title of Class of Securities)
00860C102
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
00860C102
1
Names of Reporting Persons
Pontifax VI G.P. L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
ISRAEL
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,305,846.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,305,846.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,305,846.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.8 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Consists of (a) 1,759,574 shares held by Pontifax (Israel) V, L.P., (b) 469,982 shares held by Pontifax (Cayman) V, L.P, (c) 683,616 shares held by Pontifax (China) V L.P.; and (d) 392,674 shares held by Pontifax Late Stage L.P. (collectively, the "Pontifax Entities"). Pontifax VI G.P. L.P. ("Pontifax VI GP") is the general partner of each of the Pontifax Entities. Pontifax Management 4 G.P. (2015) Ltd. ("Pontifax Management") is the general partner of Pontifax VI GP. Mr. Tomer Kariv and Mr. Ran Nussbaum are the directors of Pontifax Management. Each of Mr. Kariv and Mr. Nussbaum disclaim beneficial ownership of the shares held by the Pontifax Entities and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.
SCHEDULE 13G
CUSIP Number(s):
00860C102
1
Names of Reporting Persons
Pontifax Management 4 G.P. (2015) Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
ISRAEL
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,305,846.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,305,846.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,305,846.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.8 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: Consists of (a) 1,759,574 shares held by Pontifax (Israel) V, L.P., (b) 469,982 shares held by Pontifax (Cayman) V, L.P, (c) 683,616 shares held by Pontifax (China) V L.P.; and (d) 392,674 shares held by Pontifax Late Stage L.P. Pontifax VI GP is the general partner of each of the Pontifax Entities. Pontifax Management is the general partner of Pontifax VI GP. Mr. Tomer Kariv and Mr. Ran Nussbaum are the directors of Pontifax Management. Each of Mr. Kariv and Mr. Nussbaum disclaim beneficial ownership of the shares held by the Pontifax Entities and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.
SCHEDULE 13G
CUSIP Number(s):
00860C102
1
Names of Reporting Persons
Ran Nussbaum
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
ISRAEL
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,305,846.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,305,846.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,305,846.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.8 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Consists of (a) 1,759,574 shares held by Pontifax (Israel) V, L.P., (b) 469,982 shares held by Pontifax (Cayman) V, L.P, (c) 683,616 shares held by Pontifax (China) V L.P.; and (d) 392,674 shares held by Pontifax Late Stage L.P. Pontifax VI GP is the general partner of each of the Pontifax Entities. Pontifax Management is the general partner of Pontifax VI GP. Mr. Tomer Kariv and Mr. Ran Nussbaum are the directors of Pontifax Management. Each of Mr. Kariv and Mr. Nussbaum disclaim beneficial ownership of the shares held by the Pontifax Entities and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.
SCHEDULE 13G
CUSIP Number(s):
00860C102
1
Names of Reporting Persons
Tomer Kariv
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
ISRAEL
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,305,846.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,305,846.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,305,846.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.8 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Consists of (a) 1,759,574 shares held by Pontifax (Israel) V, L.P., (b) 469,982 shares held by Pontifax (Cayman) V, L.P, (c) 683,616 shares held by Pontifax (China) V L.P.; and (d) 392,674 shares held by Pontifax Late Stage L.P. Pontifax VI GP is the general partner of each of the Pontifax Entities. Pontifax Management is the general partner of Pontifax VI GP. Mr. Tomer Kariv and Mr. Ran Nussbaum are the directors of Pontifax Management. Each of Mr. Kariv and Mr. Nussbaum disclaim beneficial ownership of the shares held by the Pontifax Entities and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Agomab Therapeutics NV
(b)
Address of issuer's principal executive offices:
Posthoflei 1/6, Antwerpen, Belgium, 2600
Item 2.
(a)
Name of person filing:
This Statement is filed on behalf of Pontifax VI G.P. L.P., Pontifax Management 4 G.P. (2015) Ltd., Ran Nussbaum and Tomer Kariv.
(b)
Address or principal business office or, if none, residence:
The addresses of the Reporting Persons are:
Pontifax VI G.P. L.P. - 14 Shenkar St. Herzliya, 46140, Israel
Pontifax Management 4 G.P. (2015) Ltd. - 14 Shenkar St. Herzliya, 46140, Israel
Ran Nussbaum - 14 Shenkar St. Herzliya, 46140, Israel
Tomer Kariv - 14 Shenkar St. Herzliya, 46140, Israel
(c)
Citizenship:
Pontifax VI G.P. L.P. is organized in the State of Israel, Pontifax Management 4 G.P. (2015) Ltd. is incorporated in the State of Israel, and Ran Nussbaum and Tomer Kariv are citizens of the State of Israel.
(d)
Title of class of securities:
Common Shares, no nominal value per share
(e)
CUSIP Number(s):
00860C102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
3,305,846
(b)
Percent of class:
6.8%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
3,305,846
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
3,305,846
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
A. Joint Filing Agreement, dated as of April 16, 2026, by and among Pontifax VI G.P. L.P., Pontifax Management 4 G.P. (2015) Ltd., Ran Nussbaum and Tomer Kariv.
What stake does Pontifax report in Agomab Therapeutics (AGMB)?
Pontifax-related reporting persons report 3,305,846 shares, equal to 6.8% of Agomab's common stock as of 03/31/2026. The position is reported on a joint Schedule 13G with shared voting and dispositive power.
Who filed the Schedule 13G for AGMB on behalf of Pontifax?
The filing was made jointly by Pontifax VI G.P. L.P., Pontifax Management 4 G.P. (2015) Ltd., and individuals Ran Nussbaum and Tomer Kariv, under a Joint Filing Agreement dated April 16, 2026.
Does the filing show direct ownership by Ran Nussbaum or Tomer Kariv?
No. The filing states Messrs. Nussbaum and Kariv disclaim beneficial ownership of the shares held by the Pontifax entities; beneficial ownership is attributed to the four Pontifax funds named in the filing.
What voting and disposition powers are reported for the 6.8% stake?
The Schedule 13G reports 0 sole voting and 3,305,846 shared voting power, and 0 sole dispositive and 3,305,846 shared dispositive power over the common shares.
